SCHEMBL5886709

SCHEMBL5886709

COc1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(c6ccccn6)CC5)nc43)cc2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
CTNNB1 P35222 2/20 0.42
TCF7L2 Q9NQB0 2/20 0.42
RXFP1 Q9HBX9 1/20 0.41
RAB9A P51151 1/20 0.41
NAMPT P43490 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886765 0.94 MAPT (0.48) ALDH1A1HSD17B10LMNAMAPTSMN1; SMN2
SCHEMBL5887045 0.91 SMN1; SMN2 (0.49) ALDH1A1HPGDHSD17B10LMNAMAPT
SCHEMBL5886965 0.90 SLC6A4 (0.46) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5887120 0.90 CTNNB1 (0.44) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5886714 0.89 ALDH1A1 (0.45) ALDH1A1HSD17B10LMNAMAPTSMN1; SMN2
SCHEMBL5887267 0.89 CTNNB1 (0.45) ALDH1A1KDM4EHSD17B10LMNAMAPT
SCHEMBL5886820 0.88 SMN1; SMN2 (0.44) ALDH1A1HSD17B10LMNAMAPTSMN1; SMN2
SCHEMBL5887006 0.88 ACHE (0.48) ALDH1A1LMNAMAPTSMN1; SMN2NAMPT
SCHEMBL5886974 0.88 SMN1; SMN2 (0.49) ALDH1A1HPGDHSD17B10LMNAMAPT
SCHEMBL5887644 0.88 NPC1 (0.45) ALDH1A1HSD17B10LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP ALDH1A1 1860/4885KDM4E 840/4885HPGD 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.